Ilyang Pharm (007570) — Cash Flow Reinvestment Rate
Ilyang Pharm (007570) has a Cash Flow Reinvestment Rate of 3.94x as of June 2025, reinvesting ₩8.90 Billion (capex ₩3.32 Billion plus investments ₩-5.59 Billion) from operating cash flow of ₩2.26 Billion. See Ilyang Pharm (007570) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Ilyang Pharm Cash Flow Reinvestment Rate (2003–2024)
Historical reinvestment intensity for Ilyang Pharm across 12 annual periods. For the full cash flow conversion analysis, see 007570 operating cash flow.
Annual Cash Flow Reinvestment Rate for Ilyang Pharm (2003–2024)
Year-by-year capital reinvestment analysis for Ilyang Pharm. See Ilyang Pharm free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 13.86x | ₩77.80 Billion | ₩5.61 Billion | ₩40.62 Billion | ▲ +984.2% |
| 2023 | 1.28x | ₩17.05 Billion | ₩13.34 Billion | ₩6.47 Billion | ▲ +18.8% |
| 2022 | 1.08x | ₩32.20 Billion | ₩29.94 Billion | ₩4.08 Billion | ▲ +434.9% |
| 2021 | 0.20x | ₩13.48 Billion | ₩67.02 Billion | ₩12.91 Billion | ▲ +12.3% |
| 2020 | 0.18x | ₩10.29 Billion | ₩57.48 Billion | ₩10.17 Billion | ▼ -25.2% |
| 2019 | 0.24x | ₩8.67 Billion | ₩36.19 Billion | ₩2.17 Billion | ▲ +104.4% |
| 2018 | 0.12x | ₩2.59 Billion | ₩22.12 Billion | ₩1.55 Billion | ▼ -53.7% |
| 2017 | 0.25x | ₩7.60 Billion | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.4% |
| 2016 | 0.78x | ₩20.98 Billion | ₩26.98 Billion | ₩10.31 Billion | ▲ +87.2% |
| 2015 | 0.42x | ₩16.72 Billion | ₩40.27 Billion | ₩16.07 Billion | ▼ -44.4% |
| 2014 | 0.75x | ₩13.92 Billion | ₩18.63 Billion | ₩13.89 Billion | ▲ +1715.2% |
| 2003 | 0.04x | ₩415.11 Million | ₩10.08 Billion | ₩415.11 Million | — |